Ovid Therapeutics Inc. (OVID) News
Follow Ovid Therapeutics Inc. (OVID) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
OVID: Advancing novel epilepsy and CNS therapies with strong clinical progress and major market potential
Novel therapies targeting neural hyperexcitability are advancing, with OV329 showing strong safety and efficacy in epilepsy and a billion-dollar market potential. The KCC2 portfolio, including a first-in-class oral activ
NEWS | Sep 14, 2026, 06:38 PM UTC
L
Ovid Therapeutics to participate in upcoming investor conferences
Ovid Therapeutics says it will participate in upcoming investor conferences, per a company release.
EQUITY | Sep 03, 2026, 12:01 PM UTC
L
Ovid Therapeutics reports business updates and Q2 2026 results
Ovid Therapeutics (OVID) reports business updates and its second quarter 2026 financial results.
EARNINGS | Aug 13, 2026, 12:31 PM UTC
L
OVID Opportunities through YE26 for both programs, OV329 and KCC2, to unlock next leg of growth @ Briley
OVID Opportunities through YE26 for both programs, OV329 and KCC2, to unlock next leg of growth @ Briley
EQUITY | Jul 20, 2026, 01:09 PM UTC